Secondary Logo

Journal Logo

Opioid receptor bronchial tree: current science

Krajnik, Malgorzataa; Jassem, Ewab; Sobanski, Piotrc

Current Opinion in Supportive and Palliative Care: September 2014 - Volume 8 - Issue 3 - p 191–199
doi: 10.1097/SPC.0000000000000072
RESPIRATORY PROBLEMS: Edited by David C. Currow and Amy P. Abernethy
Free

Purpose of review Systemic opioids have the evidence to support their use in refractory dyspnea; however, the mechanisms of how they exert their effects are not fully understood. The relevance of peripheral mechanisms, in part, is still questioned, especially as a meta-analysis demonstrated no benefit from nebulized opioids. This might be related to the lack of standardization of the inhalation methods. There is a need to clarify whether peripheral opioid receptors may serve as the target for inhaled treatment and what are the potential peripheral mechanisms of opioids.

Recent findings Opioidergic systems are present in structures important for the regulation of bronchial and pulmonary vascular responses, as well as breathlessness perception in the human respiratory system. Opioid receptors located in the pulmonary neuroendocrine cells (PNECs) and sensory C-fibers within the bronchial epithelium are easily accessible for inhaled treatment. Morphine administrated by a pneumodosimetric method shows a different pharmacokinetic profile to those described for systemic routes, suggesting local metabolism in lung.

Summary Research suggests that peripheral opioid receptors in lungs may be utilized as a target for therapeutic interventions. According to this hypothesis, to achieve breathlessness relief, opioids should be administered in close proximity to their receptors in the PNECs and sensory C-fibers of the bronchial epithelium.

aChair of Palliative Care, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland

bDepartment of Allergology, University of Medical Sciences in Gdansk, Poland

cPalliativzentrum Hildegard, Basel, Switzerland

Correspondence to Malgorzata Krajnik, MD, PhD, Chair of Palliative Care, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Skłodowskiej-Curie 9, 85-094, Bydgoszcz, Poland. Tel: +48 525853461; fax: +48 525853461; e-mail: malgorzata.krajnik@wp.pl

Back to Top | Article Outline

INTRODUCTION

Oral and parenteral low-dose opioids have been shown to ameliorate refractory breathlessness in cancer and noncancer patients, and their use for such indications has been widely accepted in palliative and supportive care. Suggested central mechanisms whereby opioids relieve dyspnea include decreasing respiratory drive with an associated decrease in corollary discharge, reducing anxiety, and altering central perception. Whether systemically administered opioids evoke any peripheral effects remains an open question. However, attenuation of desflurane-evoked airway irritation during the induction of anesthesia [1] or reversion of ozone-provoked pulmonary function disturbances and chest pain [2] by intravenous opioids have pointed to such a possibility.

An equally intriguing question is whether intrabronchially administered opioids act locally within the respiratory system. Until now, the most proven argument for their peripheral action has been provided by experiments with isolated bronchi. In these in-vitro studies, opioids inhibited the release of proinflammatory neurotransmitters from sensory nerve endings, reversed the contraction of bronchi, and diminished mucus production [3–5]. The question of whether these effects would be observed in vivo remains unanswered. Results of the clinical trials do not help to clarify the potential peripheral mechanisms of intrabronchially administered opioids either. However, anecdotal and preliminary controlled evidence repeatedly suggest the positive effect of small doses of nebulized opioids in the palliation of breathlessness in patients with advanced cancer and cystic fibrosis, even in those receiving parenteral opioids [6–8].

Probably, the most intriguing observation was brought by Shohrati et al.[9▪] from their randomized controlled trial performed in a cohort of 40 patients with chronic obstructive pulmonary disease (COPD) in part because of inhaling sulfur mustard during military conflict. One milligram of nebulized morphine given daily for 5 days provided fast (after 15 min) and sustained reduction in patient-reported dyspnea and cough compared with nebulized physiological saline.

However, to date, nebulized opioids are not recommended for routine use in breathlessness and cough, even in palliative care, mostly because a meta-analysis of clinical studies did not demonstrate their superiority to the placebo [10]. The trials of nebulized opioids included in the analysis were carried out without standardization of the inhalation methods, as well as widely varying doses. Moreover, the desired place of drug deposition was not defined, because knowledge of opioid receptors localization in the respiratory tract was not available at that time. This, therefore, leaves open the question of the net benefits of nebulized opioids and requires further clinical studies.

This review concentrates on three main issues:

  1. whether peripheral opioid receptors may serve as the potential target for inhaled treatment;
  2. which part of the respiratory tract is a preferential area for aerosol deposition; and
  3. what opioid receptors expression on different structures in the human lung tells us regarding the potential peripheral mechanisms of opioids.
Box 1

Box 1

Back to Top | Article Outline

ENDOGENOUS OPIOID SYSTEMS IN THE HUMAN LUNG

Opioid peptides, their precursors, and their corresponding receptors are widely distributed throughout the body, not only within the nervous system, but also in the nonneuronal tissue, including the lungs. Previous studies have identified β-endorphin (END), met-enkephalin (ENK), and dynorphin (DYN) in human lung cancer cell lines [11,12]. In addition, binding experiments have demonstrated the presence of opioid-binding sites in the homogenates of both rat and human lung [13], as well as in the human lung carcinoma cell lines [11]. Unfortunately, such methods did not allow for description of the cellular and regional distribution of opioid systems in the respiratory tract. It has only recently been demonstrated by immunohistochemical examination that the basic components of the endogenous opioid network can be found in different areas of lung tissue from lung cancer patients [14,15,16].

Active peptides (END, ENK, and DYN), their precursors (proopiomelanocortin, proenkephalin, and prodynorphin), enzymes necessary for the transition of precursors into active opioids (prohormone convertase 1 and 2, carboxypeptidase E), and the corresponding opioid receptors [μ-opioid receptor (MOR), δ-opioid receptor (DOR), and κ-opioid receptor (KOR)] have been identified on particular cells (Table 1). The presence of all the above components suggests the local synthesis of endogenous opioids. However, the clinical relevance of this phenomenon remains unclear. Thus, a further part of this review will focus on the opioid receptors which seem to be accessible for inhaled treatment.

Table 1

Table 1

Back to Top | Article Outline

OPIOID RECEPTOR BRONCHIAL TREE CONCEPT

In clinical practice, most inhaled agents require deposition in the most distant regions of the bronchial tree. Contrary to this, the recent evidence regarding opioid systems in the human lung suggest that opioid delivered in breathlessness and cough should be directed preferentially to the trachea and proximal bronchial tree. As opioid receptors are localized on the pulmonary neuroendocrine cells (PNECs) and C nerve fibers arborizing to the superficial layer of bronchial epithelium (Figs 1 and 2) [14,15], they might be easily accessible for inhaled treatment. The presence of opioid receptors close to the lumen suggests that even hydrophilic substances such as morphine should exert their action in intact epithelium after nebulization.

FIGURE 1

FIGURE 1

FIGURE 2

FIGURE 2

Together, opioid receptors in the PNEC–C nerve fiber network within the tracheobronchial epithelium seem to be quite likely targets for inhaled treatment. How intrabronchial opioids might work locally depends mostly on the roles played by PNECs and afferent nerves within the respiratory system.

Back to Top | Article Outline

Pulmonary neuroendocrine cells as potential main sensors in the human lung

The PNEC network consists of solitary PNECs, widely distributed within the mucosa of the tracheobronchial tree, and their clusters, known as neuroepithelial bodies (NEBs), which are localized, at least in animals, primarily in the intrapulmonary airways (for review see [17▪▪]).

PNECs and NEBs have been implicated in the regulation of lung function, including airway oxygen sensing, control of bronchial tone and pulmonary blood flow, modulation of immune responses, and maintenance of a stem cell niche [18▪,19]. In early lung development, PNECs and NEBs modulate fetal lung growth and differentiation, whereas in the perinatal period they serve as polymodal airway sensors that monitor changes in airway gas concentration and respond to hypoxia, hypercapnia, and acidosis. Whether adult human lungs can also directly sense oxygen concentration in inhaled air remains uncertain and requires further studies. One of the main difficulties in the interpretation of experiments involving PNECs and NEBs in humans is because of the fact that most studies have been performed on animals. The PNEC network differs in the morphology, localization, and function between species. For example, human PNECs are smaller than the PNECs in rat, have an interdigitating morphology, are located within epithelium (but not in the subepithelial layer), and, of note, are found in the trachea and major bronchi, but not in alveolar tissue [20▪▪]. The concept of PNECs as airway sensors is supported by the presence of their cellular digits projecting toward the apical surface (Fig. 2c and d) [15] and direct innervation by the afferent neuronal fibers [20▪▪,21]. Recent data suggest that human adult solitary PNECs serve mainly as airway chemosensory neuroendocrine sentinels in epithelium. They may give rise to neural and paracrine and endocrine reactions through the release of serotonin (5-HT), calcitonin gene-related peptide (CGRP), and other mediators which subsequently modify the smooth muscle tone of bronchial and pulmonary vessels, modulate inflammatory responses, and initiate sensory neural transmission to the central nervous system (CNS) mainly via vagal afferent fibers [20▪▪]. It should be noted that PNECs possess release mechanisms tailored to different stimuli. Hypoxia is detected by the NADPH oxidase coupled to a variety of O2-sensitive voltage-dependent K+ channel proteins [18▪]. The subsequent closure of K+ channels causes membrane depolarization, activation of voltage-gated Ca2+ channels that in turn leads to the influx of Ca2+, and triggers the exocytosis of 5-HT and neuropeptides. 5-HT activates both postsynaptic receptors on nerve endings and paracrine and autocrine receptors (including 5-HT-3 found in human PNECs and NEBs proposed to act as autoreceptors in positive feedback modulation) [22]. Together, 5-HT release initiates hypoxia chemotransmission to CNS to modulate breathing (via vagal afferents) and local effects, leading to the increase of blood flow in better ventilated portions of the lung.

Mechanical stimulation of PNECs and NEBs, in contrast, leads to the opening of the transient receptor potential canonical-5 (TRPC5) channel with subsequent calcium-dependent exocytosis of ATP [23▪,24]. ATP activates the purinergic (P2X2/3) receptors on vagal afferents allowing fast conduction to the CNS and on Clara-like cells within the epithelium as paracrine signaling [23▪]. Less is known on the chemosensory function of PNECs. However, recently adult human PNECs have been shown to express different olfactory receptors and release of 5-HT and CGRP under the stimulation with volatile chemicals [20▪▪]. Although sensory function of PNECs remains to be investigated, it is possible that the specific pathways of PNECs activation may be a therapeutic target.

The potential role of PNECs in the pathophysiology of dyspnea is at present speculative. Interestingly, plasma concentration of chromogranin A, a neurosecretion marker of PNECs, has recently been demonstrated as a strong and independent predictor of all-cause mortality at 1 year in patients with acute dyspnea in an emergency setting [25]. What is more, different pulmonary disorders leading to dyspnea, including pulmonary hypertension, cystic fibrosis, small-cell lung carcinoma, chronic bronchitis, or emphysema, are associated with PNEC and NEB dysplasia or dysfunction [26]. The higher expression of PNECs in the lungs of COPD patients, along with a changed distribution of 5-HT and CGRP receptors, suggests an increased PNEC-dependent chemoresponsiveness in this disease [20▪▪].

Together, these data indicate that adult human PNECs might represent a cellular target for the management of breathlessness. The potential for opioids to act at PNECs had been suggested by old experiments, such as the inhibition of 5-HT secretion from PNEC-derived cancer cell culture by a DOR agonist [27] or opioid-induced relief of breathlessness and bronchoconstriction provoked by ozone, known as a strong stimulus for PNEC activation [2]. The demonstration of the presence of MOR, DOR, and KOR on PNECs in human bronchial epithelium opened a new gateway to research on potential opioid agonist involvement in the neurohormonal regulation of pulmonary vascular or bronchial responses, as well as breathlessness perception.

Back to Top | Article Outline

Neurogenic inflammation in the airways

Irritation of the sensory C nerve endings by 5-HT or CGRP released from PNECs initiates afferent signals, as well as stimulates the synthesis, antidromic transport, and peripheral release of neuropeptides (such as substance P, neurokinin A, or CGRP; Fig. 3a).

FIGURE 3

FIGURE 3

This last phenomenon leads to vasodilatation, recruitment, and activation of immune cells and stimulation of mucus secretion, all of which contribute to the neurogenic inflammation [28▪].

The major role in this process seems to be played by the transient receptor potential vanilloid type 1 (TRPV1) receptor, a nonselective cation channel expressed in the sensory neurons and various nonneuronal cells including human bronchial epithelial cells [29▪,30].

The activation of TRPV1 receptors by chemical irritants, inflammatory mediators, and tissue damaging stimuli leads to the release of neuropeptides [31,32]. TRPV1-mediated proinflammatory pathways may be responsible for whetting the inflammation and in consequence worsening of the disease, as it has been recently suggested by TRPV1 overexpression observed in patients with steroid-refractory asthma [33]. Interestingly, it has been shown that opioids inhibit the activity of TRPV1 and this inhibition is MOR specific, mediated via Gi/o proteins and the cyclic AMP and protein kinase A (cAMP–PKA) pathway [34].

The expression of opioid receptors on sensory C nerve fibers and the opioid-related inhibition of neuropeptide release appear to be a very attractive hypothesis regarding the potential anti-inflammatory effects of opioids. Such mechanisms have been proven to function in other organ systems, making the hypothesis even more attractive.

Back to Top | Article Outline

Opioid-modulated PNEC-C nerve fibers-CNS pathway

Summarizing all the mechanisms described above, it can be hypothesized that opioids administered into the tracheobronchial region inhibit PNEC and C nerve fibers activity and, consequently, both signal transmission to CNS and neurogenic inflammation in the periphery (Fig. 3b).

Back to Top | Article Outline

POTENTIAL UNIQUE ROLE OF MORPHINE IN THE LUNG

The efficacy of nebulized opioids in breathlessness might depend not only on the method of inhalation, but also on the choice of opioid. The potential impact of these two factors was recently demonstrated [35]. Morphine was administered with the Bronchial Control Treatment System-Sidestream (BCTS-S), a new dosimetric pneumatic method allowing the preferential deposition of opioid in the trachea and major bronchi [36]. With this delivery system, morphine underwent a different kind of metabolism than when administered orally or intravenously [35]. The Tmax for the metabolites of morphine after nebulization was shorter (20–30 min) and the proportion of its metabolite, morphine-6-glucuronide (M6G), was higher when compared with systemic administration. It might be hypothesized that glucuronidase UGT 2B7, which was shown to be present in the bronchial epithelium [37], preferentially produced M6G at a lower concentration of morphine [38]. Together, these facts suggest that nebulized morphine is metabolized locally in the lungs. M6G is a stronger opioid receptor agonist than the parent drug and acts predominantly peripherally because of the limited blood–brain barrier permeability [39]. It is possible that a small dose of morphine administered into the tracheobronchial region evokes predominantly peripheral effects via locally produced M6G acting on the opioid receptors expressed on PNECs–C nerve fibers network.

Back to Top | Article Outline

CONCLUSION

Opioid receptors are present in the human lung on structures directly communicating with, or localized close to, airway lumens, which play the role of chemosensitive sentinels and are crucial for the regulation of breathing and dyspnea perception. These structures are responsible for the transduction and transmission (both to and from CNS) of information needed to optimize gas exchange and to modulate respiration. In pathophysiology, these pathways participate in the generation of breathlessness or cough. It is well known that systemic opioids acting on the CNS can influence the functioning of this circuit. However, recent evidence has shown peripheral pathways are well organized and can be a target for the therapeutic interventions. In order to achieve direct peripheral effects for breathlessness relief, opioids should probably be administered in close proximity to their receptors, located in the PNECs and sensory C-fibers of the bronchial epithelium. The choice of opioids is important as they may have different modes of action and efficacy within the respiratory system. To give an example, topical morphine action might at least partially depend on the local generation of M6G, which is mainly peripherally acting and a more potent opioid agonist than its parent drug.

Altogether, the peripheral opioid receptors in PNECs and C nerve fibers within the bronchial epithelium may be utilized as a target for therapeutic efforts.

Recent data indicate that PNECs and bronchial sensory C-fibers play crucial roles in many processes, including breathlessness, cough, inflammation, and wound healing. More studies are needed to clarify to what extent topical or systemic administration of opioids might modify their function.

Back to Top | Article Outline

Acknowledgements

Funding sources: none.

Back to Top | Article Outline

Conflicts of interest

The authors declare that they do not have any potential conflicts of interest directly relating to the work presented in this article. All the authors have seen, reviewed, and approved this article. All authors have completed and signed the copyright transfer forms, and these have been included with the article submission.

Back to Top | Article Outline

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest
Back to Top | Article Outline

REFERENCES

1. Kong CF, Chew ST, Ip-Yam PC. Intravenous opioids reduce airway irritation during induction of anaesthesia with desflurane in adults. Br J Anaesth 2000; 85:364–367.
2. Passannante AN, Hazucha MJ, Bromberg PA, et al. Nociceptive mechanisms modulate ozone-induced human lung function decrements. J Appl Physiol 1998; 85:1863–1870.
3. Ray NJ, Jones AJ, Keen P. Morphine, but not sodium cromoglycate, modulates the release of substance P from capsaicin-sensitive neurones in the rat trachea in vitro. Br J Pharmacol 1991; 102:797–800.
4. Rogers DF, Barnes PJ. Opioid inhibition of neutrally mediated mucus secretion in human bronchi. Lancet 1989; 1:930–932.
5. Baroffio M, Crimi E, Rehder K, Brusasco V. Effects of κ- and μ-opioid agonists on cholinergic neurotransmission and contraction in isolated bovine trachealis. Respir Physiol Neurobiol 2013; 185:281–286.
6. Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage 2008; 36:29–38.
7. Bruera E, Sala R, Spruyt O, et al. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage 2005; 29:613–618.
8. Coyne PJ. The use of nebulized fentanyl for the management of dyspnea. Clin J Oncol Nurs 2003; 7:334–335.
9▪. Shohrati M, Ghanei M, Harandi AA, et al. Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study. Pulm Med 2012; 2012:6109–6121.

A randomized controlled trial demonstrating the effectiveness of low-dose nebulized morphine in breathlessness in the patients with COPD and chronic lung damage because of sulfur mustard inhalation.

10. Jennings AL, Davis AN, Higgins JPT, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57:939–944.
11. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA 1990; 87:3294–3298.
12. Roth KA, Barchas JD. Small cell carcinoma cell lines contain opioid peptides and receptors. Cancer 1986; 57:769–773.
13. Cabot PJ, Dodd PR, Cramond T, Smith MT. Characterization of nonconventional opioid binding sites in rat and human lung. Eur J Pharmacol 1994; 268:247–255.
14. Krajnik M, Schäfer M, Sobański P, et al. Local pulmonary opioid network in patients with lung cancer: a putative modulator of respiratory function. Pharmacol Rep 2010; 62:139–149.
15. Krajnik M, Schäfer M, Sobański P, et al. Enkephalin, its precursor, processing enzymes, and receptor as part of a local opioid network throughout the respiratory system of lung cancer patients. Hum Pathol 2010; 41:632–642.
16. Mousa SA, Krajnik M, Sobański P, et al. Dynorphin expression, processing and receptors in the alveolar macrophages, cancer cells and bronchial epithelium of lung cancer patients. Histol Histopathol 2010; 25:755–764.
17▪▪. Cutz E, Pan J, Yeger H, et al. Recent advances and controversies on the role of pulmonary neuroepithelial bodies as airway sensors. Semin Cell Dev Biol 2013; 24:40–50.

This is an excellent review on the recent findings in the biology of neuroepithelial body cells and their potential role as airway sensors.

18▪. Buttigieg J, Pan J, Yeger H, Cutz E. NOX2 (gp91phox) is a predominant O2 sensor in a human airway chemoreceptor cell line: biochemical, molecular, and electrophysiological evidence. Am J Physiol Lung Cell Mol Physiol 2012; 303:L598–L607.

The results of this experimental study suggest the predominant model of O2 sensing in human pulmonary neuroendocrine cell network.

19. Song H, Yao E, Lin C, et al. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci USA 2012; 109:17531–17536.
20▪▪. Gu X, Karp PH, Brody SL, et al. Chemosensory functions for pulmonary neuroendocrine cells. Am J Respir Cell Mol Biol 2014; 50:637–646.

This study shows that solitary pulmonary neuroendocrine cells might serve as chemosensory cells in the human airways.

21. Weichselbaum M, Sparrow MP, Hamilton EJ, et al. A confocal microscopic study of solitary pulmonary neuroendocrine cells in human airway epithelium. Respir Res 2005; 6:115.
22. Fu XW, Wang D, Pan Y, et al. Neuroepithelial bodies in mammalian lung express functional serotonin-type 3 (5-HT3) receptor. Am J Physiol 2001; 281:L931–L940.
23▪. Lembrechts R, Brouns I, Schnorbusch K, et al. Neuroepithelial bodies as mechanotransducers in the intrapulmonary airway epithelium: involvement of TRPC5. Am J Respir Cell Mol Biol 2012; 47:315–323.

This experimental study using an animal model demonstrates how pulmonary neuroepithelial cells may function as transducers of intrapulmonary mechanical information.

24. Lembrechts R, Brouns I, Schnorbusch K, et al. Functional expression of the multimodal extracellular calcium-sensing receptor in pulmonary neuroendocrine cells. J Cell Sci 2013; 126:4490–4501.
25. Dieplinger B, Gegenhuber A, Kaar G, et al. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 2010; 43:714–719.
26. Domnik NJ, Cutz E. Pulmonary neuroepithelial bodies as airway sensors: putative role in the generation of dyspnea. Curr Opin Pharmacol 2011; 11:211–217.
27. Sher E, Cesare P, Codignola A, et al. Activation of δ-opioid receptors inhibits neuronal-like calcium channels and distal steps of Ca2+-dependent secretion in human small-cell lung carcinoma cells. J Neurosci 1996; 16:3672–3684.
28▪. Assas BM, Pennock JI, Miyan JA. Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis. Front Neurosci 2014; 8:23eCollection 2014.

This is an interesting overview of the place of CGRP as a key mediator of neuroimmune communication with the C fibers, acting as both sensory pathways and as a local controller of immune functions.

29▪. Grace MS, Baxter M, Dubuis E, et al. Transient receptor potential (TRP) channels in the airway: role in airway disease. Br J Pharmacol 2014; 171:2593–2607.

A very useful review which summarizes the existing literature on the role of TRP channels in the lungs and discusses what is known about their function under normal and diseased conditions.

30. McGarvey LP, Butler CA, Stokesberry S, et al. Increased expression of bronchial epithelial transient receptor potential vanilloid 1 channels in patients with severe asthma. J Allergy Clin Immunol 2014; 133:704.e4–712.e4.
31. Yu H, Li Q, Zhou X, et al. Transient receptor potential vanilloid 1 receptors mediate acid-induced mucin secretion via Ca2+ influx in human airway epithelial cells. J Biochem Mol Toxicol 2012; 26:179–186.
32. Sadofsky LR, Ramachandran R, Crow C, et al. Inflammatory stimuli up-regulate transient receptor potential vanilloid-1 expression in human bronchial fibroblasts. Exp Lung Res 2012; 38:75–81.
33. Thomas KC, Roberts JK, Deering-Rice CE, et al. Contributions of TRPV1, endovanilloids, and endoplasmic reticulum stress in lung cell death in vitro and lung injury. Am J Physiol Lung Cell Mol Physiol 2012; 302:L111–L119.
34. Endres-Becker J, Heppenstall PA, Mousa SA, et al. μOpioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain. Mol Pharmacol 2007; 71:12–18.
35. Krajnik M, Podolec Z, Siekierka M, et al. Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain Symptom Manage 2009; 38:747–757.
36. Krajnik M, Podolec Z, Zylicz Z, et al. Air humidity may influence the aerosol distribution of normal saline administered by closed or vented nebulizers operated continuously or dosimetrically. J Aerosol Med Pulm Drug Deliv 2009; 22:29–34.
37. Ren Q, Murphy SE, Zheng Z, Lazarus P. O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 2000; 28:1352–1360.
38. Yamada H, Ishii K, Ishii Y, et al. Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci 2003; 28:395–401.
39. Bouw MR, Tunblad K, Hammarlund-Udenaes M. Blood brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats – pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol 2001; 134:1796–1804.
Keywords:

C nerve fibers; neurogenic inflammation; opioid receptors; pulmonary neuroendocrine cells

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins